56 completed, 13 unknown, 10 terminated, 5 recruiting. 86 Phase 2, 17 Phase 3, 10 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 86 | Completed 56, Unknown 13, Terminated 10, Recruiting 5, Withdrawn 2 |
| Phase 3 | 17 | Completed 11, Unknown 4, Terminated 2 |
| Phase 1 | 10 | Completed 6, Withdrawn 2, Terminated 1, Unknown 1 |
Follow Euglenozoa Infections: new trials by email Literature Review of Euglenozoa Infections trials Research Report on Euglenozoa Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease. LXE408, Placebo, Benznidazole - Chagas Disease | Phase 2 | Recruiting | Novartis Pharmaceuticals | 130 | 2025-04-28 | 2026-11-10 |
| Intralesional Injection of Metronidazole for the Management of Cutaneous Leishmaniasis Metronidazole - Cutaneous Leishmaniasis | Phase 2 | Recruiting | Hayder Adnan Fawzi | 40 | 2025-02-10 | 2025-02-14 |
| Intralesional Injection of Levofloxacin for the Management of Cutaneous Leishmaniasis Levofloxacin 0.5% - Cutaneous Leishmaniasis | Phase 2 | Recruiting | Hayder Adnan Fawzi | 40 | 2025-02-09 | 2025-09-30 |
| Ciprofloxacin Intralesional Injection for the Treatment of Cutaneous Leishmaniasis Compared to Sodium Stibogluconate Ciprofloxacin (BAYO9867), sodium stibogluconate (Pentostam) - Cutaneous Leishmaniasis | Phase 2 | Recruiting | Al-Mustafa University College | 80 | 2025-02-07 | 2025-09-30 |
| Treatment of Bolivian L Braziliensis Mucosal Leishmaniasis With Inhaled Pentamidine Plus Oral Miltefosine Miltefosine Oral Capsule - Mucosal Leishmaniasis | Phase 2 | Recruiting | Fundacion Nacional de Dermatologia | 30 | 2025-02-04 | 2025-02-26 |
| Tofacitinib Associated With Meglumine Antimoniate in Cutaneous Leishmaniasis Oral tofacitinib, Parenteral meglumine antimoniate - Cutaneous Leishmaniasis, American | Phase 2 / Phase 3 | Unknown | Hospital Universitário Professor Edgard Santos | 22 | 2023-10-01 | 2023-08-25 |
| Pharmacokinetic, Efficacy, Safety and Tolerability Study of a Single Dose of Acoziborole in g-HAT Paediatric Patients Acoziborole - Trypanosomiasis, African, Trypanosoma Brucei Gambiense; Infection | Phase 2 / Phase 3 | Completed | Drugs for Neglected Diseases | 35 | 2022-07-09 | 2026-04-06 |
| Pilot Study: Oral Treatment of American Tegumentary Leishmaniasis (Cutaneous and Mucosal Forms) in the Elderly Miltefosine 50mg, Pentoxifylline 400mg, Liposomal Amphotericin B - Leishmaniasis; Brazilian, Leishmaniasis, Mucocutaneous | Phase 2 / Phase 3 | Unknown | University of Brasilia | 100 | 2022-06-22 | 2023-09-15 |
| Safety and Tolerability Study of Acoziborole in g-HAT Seropositive Subjects Acoziborole, Placebo - Trypanosomiasis, African, Trypanosoma Brucei Gambiense; Infection | Phase 2 / Phase 3 | Completed | Drugs for Neglected Diseases | 1208 | 2021-12-30 | 2025-03-20 |
| Atorvastatin on Inflammation and Cardiac Function in Chronic Chagas Disease 40 mg Atorvastatin/day for 120 days P.O., Atorvastatin 80, Placebo - Chronic Chagas Disease | Phase 2 | Terminated | Juan D. Maya | 300 | 2021-10-12 | 2024-09-19 |
| SBRT in Chagas Disease Ventricular Tachycardia Stereotactic Body Radiation Therapy - Ventricular Tachycardia, Chagas Disease | Phase 1 / Phase 2 | Unknown | University of Sao Paulo General Hospital | 10 | 2021-07-14 | 2024-07-16 |
| Phase 2 Trial to Evaluate 18-Methoxycoronaridine Efficacy, Safety and Tolerability in Cutaneous Leishmaniasis Patients 18-Methoxycoronaridine, Glucantime - Leishmaniasis; American, Cutaneous, Drug Side Effect | Phase 2 | Unknown | Infan Industria Quimica Farmaceutica Nacional | 52 | 2021-05-01 | 2020-03-19 |
| Evaluation of the Safety and Clinical Activity of Curaleish in the Topical Treatment of Cutaneous Leishmaniasis. Experimental topical (Curaleish Topical) - Leishmaniasis, Cutaneous | Phase 1 / Phase 2 | Withdrawn | Universidad de Antioquia | 2021-01-01 | 2022-06-03 | |
| A Study to Assess the Safety, Efficacy and Immunogenicity of Leishmania Vaccine ChAd63-KH in PKDL ChAd63-KH, Placebo - Leishmaniasis, Cutaneous | Phase 2 | Completed | University of York | 86 | 2020-04-06 | 2023-05-26 |
| New Therapies and Biomarkers for Chagas Infection Benznidazole, Nifurtimox - Trypanosoma Cruzi Infection, Chagas Disease | Phase 2 | Completed | University of Texas, El Paso | 450 | 2019-12-18 | 2024-07-17 |
| Fexinidazole in Human African Trypanosomiasis Due to T. b. Rhodesiense Fexinidazole - Trypanosomiasis, African, Sleeping Sickness | Phase 2 / Phase 3 | Completed | Drugs for Neglected Diseases | 45 | 2019-09-29 | 2025-01-30 |
| Treatment of Cutaneous Leishmaniasis With Liposomal Amphotericin B in the Elderly Liposomal amphotericin B (AmBisome®) - Cutaneous Leishmaniasis, American | Phase 1 / Phase 2 | Completed | Hospital Universitário Professor Edgard Santos | 28 | 2019-03-01 | 2024-06-07 |
| Oral Miltefosine Plus Topical Paromomycin In American Cutaneous Leishmaniasis Miltefosine and Paromomycin, miltefosine, paromomycin - Cutaneous Leishmaniasis, American | Phase 2 / Phase 3 | Completed | Fundacion Nacional de Dermatologia | 120 | 2019-02-01 | 2021-02-02 |
| Topical Sm29 in Combination With Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis. Sm29 Protein, Schistosoma Mansoni, Pentavalent antimony (Sbv) - Cutaneous Leishmaniasis, American | Phase 1 / Phase 2 | Completed | Hospital Universitário Professor Edgard Santos | 20 | 2019-01-17 | 2023-08-21 |
| Colchicine for Patients With Chagas´ Disease( B1 Stage) Colchicine 0.5 MG twice day for one year, Placebo Oral Tablet - Chagas Disease, Colchicine Resistance | Phase 2 | Unknown | University of Sao Paulo General Hospital | 60 | 2018-10-01 | 2019-03-11 |
Showing 20 of 86. Sign in to see all of them.
Leishmaniasis, Cutaneous (40) · Leishmaniasis (27) · Chagas Disease (15) · Leishmaniasis, Mucocutaneous (12) · Leishmaniasis, Visceral (9) · Trypanosomiasis, African (8) · Infections (3) · Bronchiolitis Obliterans Syndrome (2) · Inflammation (2) · Arrhythmias, Cardiac (1) · Chagas Cardiomyopathy (1) · Communicable Diseases (1) · Drug-Related Side Effects and Adverse Reactions (1) · Fibrosis (1) · Hypersensitivity, Delayed (1)
Protozoan Infections (86) · Vector Borne Diseases (86) · Parasitic Diseases (85) · Infections (83) · Skin Diseases, Infectious (54) · Skin Diseases, Parasitic (54) · Skin and Connective Tissue Diseases (54) · Skin Diseases (53) · Leishmaniasis (36) · Trypanosomiasis (23) · Leishmaniasis, Cutaneous (6) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Immune System Diseases (3)
miltefosine (19) · Meglumine Antimoniate (11) · benzonidazole (8) · liposomal amphotericin B (7) · Antimony Sodium Gluconate (6) · Paromomycin (6) · fexinidazole (5) · Pentoxifylline (4) · Nifurtimox (3) · Pentamidine (3) · Amphotericin B (2) · Antimony (2) · Cryotherapy (2) · Eflornithine (2) · Prodrugs (2)
Drugs for Neglected Diseases (15) · U.S. Army Medical Research and Development Command (10) · Hospital Universitário Professor Edgard Santos (6) · AB Foundation (4) · Fundacion Nacional de Dermatologia (4) · Banaras Hindu University (3) · Access to Advanced Health Institute (AAHI) (2) · Foundation Fader (2) · Hayder Adnan Fawzi (2) · Hospital Universitari Vall d'Hebron Research Institute (2) · Immtech Pharmaceuticals, Inc (2) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Oswaldo Cruz Foundation (2) · University of Brasilia (2) · University of Sao Paulo General Hospital (2)
Brazil (20) · Bolivia (14) · Colombia (8) · United States (8) · India (5) · Sudan (5) · Democratic Republic of the Congo (4) · Guinea (3) · Iraq (3) · Peru (3) · Republic of the Congo (3) · Spain (3) · Tunisia (3) · Uganda (3) · Argentina (2)
Shyam Sundar, MD (3) · Afif Ben Salah, M.D., Ph.D. (2) · Armando O. Schubach, MD, PhD (2) · Faustino Torrico, PhD (2) · Isabela Ribeiro, MD (2) · Ivan Dario Velez, Prof (2) · Jaime Soto, MD (2) · Paulo RL Machado, MD, PhD (2) · Afif Ben Salah,, MD, PhD (1) · Ahmed M Musa, MD PhD (1) · Ahmed Musa, MBBS (1)
PMID 23877689, PMID 26881924, PMID 18781879, PMID 19415122, PMID 20231896, PMID 20438389, PMID 21129762, PMID 21200420, PMID 21375777, PMID 21633025, PMID 21718522, PMID 23390069, PMID 24454970, PMID 24827034, PMID 26573827, PMID 27627654, PMID 27927991, PMID 28231946, PMID 28379954, PMID 28558061, PMID 29113731, PMID 29352704, PMID 30044792, PMID 30188978, PMID 30260376, PMID 30379814, PMID 30509941, PMID 31307503, PMID 32293523, PMID 33781913, PMID 33836161, PMID 34972765, PMID 35255096, PMID 35757326, PMID 35925555, PMID 36395328, PMID 36409773, PMID 36460027, PMID 36638112, PMID 37252616, PMID 38218194, PMID 38218195, PMID 39147194, PMID 39253357, PMID 39627222, PMID 40288400, PMID 40982532, PMID 42772313
2016 (3), U01AI129783 (1)